Clinical Research Directory
Browse clinical research sites, groups, and studies.
NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
Sponsor: Neurocrine Biosciences
Summary
The study will evaluate the efficacy of NBI-1065845 compared with placebo as an adjunctive treatment in participants with MDD on improving symptoms of depression.
Official title: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-1065845 as Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
200
Start Date
2025-05-30
Completion Date
2027-07
Last Updated
2025-12-22
Healthy Volunteers
No
Conditions
Interventions
NBI-1065845
NBI-1065845 tablets
Placebo
Matching placebo tablets
Locations (16)
Neurocrine Clinical Site
Los Angeles, California, United States
Neurocrine Clinical Site
Aurora, Colorado, United States
Neurocrine Clinical Site
Cromwell, Connecticut, United States
Neurocrine Clinical Site
Farmington, Connecticut, United States
Neurocrine Clinical Site
Maitland, Florida, United States
Neurocrine Clinical Site
Tampa, Florida, United States
Neurocrine Clinical Site
Gaithersburg, Maryland, United States
Neurocrine Clinical Site
Cedarhurst, New York, United States
Neurocrine Clinical Site
New York, New York, United States
Neurocrine Clincial Site
New York, New York, United States
Neurocrine Clinical Site
Alken, Belgium
Neurocrine Clinical Site
Mechelen, Belgium
Neurocrine Clinical Site
Oulu, Finland
Neurocrine Clinical Site
Jelgava, Latvia
Neurocrine Clinical Site
Liepāja, Latvia
Neurocrine Clinical Site
Sigulda, Latvia